Canadian panel says Vioxx is safe enough to return to market

Share this article:

By a vote of 12 to 1, a panel of Canadian health advisors said Thursday that Merck's COX-2 drug Vioxx should be allowed to go on sale again in the country.
The panel said the risk of heart disease from Vioxx was the same as posed by similar painkillers and that gastrointestinal effect appeared to be less.
The panel met last month to discuss the risks of Vioxx and Pfizer's Bextra and Celebrex.
The group of advisors was unanimous in recommending Celebrex be allowed to remain on the market but voted against reintroducing Bextra because of its risk of a rare but serious skin disorder.
A Merck spokesperson told Reuters on Thursday the company has not decided whether to put Vioxx back on the market in Canada or anywhere else.

 

 

 

 

 

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.